AVS Bio acquires ImmunoPrecise Antibodies Europe unit

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. GOOGL
2. ENPH
3. NOW
4. MSFT
5. HOOD
6. SPY
7. BA
8. STX
9. NXPI
10. CSGP

Go back to AVS Bio acquires ImmunoPrecise Antibodies Europe unit

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodi

August 6, 2025 8:00 AM EDT

WASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)-- Arlington Capital Partners (Arlington), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. (IPA Europe or the Company). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bios European footprint and adds... More